URGN vs VERU

UroGen Pharma Ltd. vs Veru Inc. — Valuation Comparison 2026

URGN

Biotechnology
UroGen Pharma Ltd.
Quality
6.5
out of 10
Value Trap
24
SAFE
Price
$28.69
Last close
Models
11/13
Active
VS

VERU

Biotechnology
Veru Inc.
Quality
4.6
out of 10
Value Trap
25
LOW
Price
$2.32
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType URGN Fair ValueURGN Upside VERU Fair ValueVERU Upside
Bayesian DCF Intrinsic $7.27 -74.7% $1.49 -35.8%
Earnings Power Value Intrinsic $3.35 -85.4%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $14.58 -40.7% $3.71 +60.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for URGN vs VERU — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

URGN vs VERU — Which Stock Is More Undervalued?

URGN scores higher with a 6.5/10 quality rating vs VERU's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing UroGen Pharma Ltd. (URGN) and Veru Inc. (VERU) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

URGN currently trades at $28.69 with a QOC of 6.5/10, while VERU trades at $2.32 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).